Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 195

1.

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.

Manceau G, Marisa L, Boige V, Duval A, Gaub MP, Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, Lecorre D, Guenot D, Etienne-Grimaldi MC, Kirzin S, Martin L, Lepage C, Bouvier AM, Laurent-Puig P.

Cancer Med. 2015 Mar;4(3):371-82. doi: 10.1002/cam4.370. Epub 2015 Feb 2.

2.

Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.

Sibertin-Blanc C, Mancini J, Fabre A, Lagarde A, Del Grande J, Levy N, Seitz JF, Olschwang S, Dahan L.

Dig Liver Dis. 2015 Apr;47(4):331-7. doi: 10.1016/j.dld.2014.12.013. Epub 2014 Dec 30.

PMID:
25617075
3.

Genomic variations integrated database for MUTYH-associated adenomatous polyposis.

Grandval P, Fabre AJ, Gaildrat P, Baert-Desurmont S, Blayau M, Buisine MP, Coulet F, Maugard C, Pinson S, Remenieras A, Rouleau E, Uhrhammer N, Beroud C, Olschwang S.

J Med Genet. 2015 Jan;52(1):25-7. doi: 10.1136/jmedgenet-2014-102752. Epub 2014 Nov 3. No abstract available.

PMID:
25368107
4.

Frequent intragenic rearrangements of DPYD in colorectal tumours.

van Kuilenburg AB, Etienne-Grimaldi MC, Mahamat A, Meijer J, Laurent-Puig P, Olschwang S, Gaub MP, Hennekam RC, Benchimol D, Houry S, Letoublon C, Gilly FN, Pezet D, Andre T, Faucheron JL, Abderrahim-Ferkoune A, Vijzelaar R, Pradere B, Milano G.

Pharmacogenomics J. 2015 Jun;15(3):211-8. doi: 10.1038/tpj.2014.68. Epub 2014 Oct 28.

PMID:
25348620
5.

Clinical Utility Gene Card for: Familial adenomatous polyposis (FAP) and attenuated FAP (AFAP)--update 2014.

Aretz S, Vasen HF, Olschwang S.

Eur J Hum Genet. 2015 Jun;23(6). doi: 10.1038/ejhg.2014.193. Epub 2014 Sep 24. No abstract available.

PMID:
25248397
6.

Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.

Etienne-Grimaldi MC, Mahamat A, Chazal M, Laurent-Puig P, Olschwang S, Gaub MP, Formento JL, Formento P, Sudaka A, Boige V, Abderrahim-Ferkoune A, Benchimol D, André T, Houry S, Faucheron JL, Letoublon C, Gilly FN, Delpero JR, Lasser P, Pradere B, Pezet D, Penault-Llorca F, Milano G.

Br J Cancer. 2014 May 27;110(11):2728-37. doi: 10.1038/bjc.2014.213. Epub 2014 May 6.

7.

High-resolution analysis of DNA copy number alterations in rectal cancer: correlation with metastasis, survival, and mRNA expression.

Doyen J, Letouzé E, Marisa L, de Reyniès A, Milano G, Etienne-Grimaldi MC, Olschwang S, Gaedcke J, Ghadimi M, Gérard JP.

Strahlenther Onkol. 2014 Oct;190(11):1028-36. doi: 10.1007/s00066-014-0659-4. Epub 2014 Apr 26.

PMID:
24770938
8.

The UMD-APC database, a model of nation-wide knowledge base: update with data from 3,581 variations.

Grandval P, Blayau M, Buisine MP, Coulet F, Maugard C, Pinson S, Remenieras A, Tinat J, Uhrhammer N, Béroud C, Olschwang S.

Hum Mutat. 2014 May;35(5):532-6. doi: 10.1002/humu.22539. Epub 2014 Apr 7.

PMID:
24599579
9.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J.

J Mol Diagn. 2014 Jan;16(1):45-55. doi: 10.1016/j.jmoldx.2013.07.009. Epub 2013 Oct 30.

PMID:
24183959
10.

Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.

Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara C, Nowak F, Khayat D, Nogues C.

Breast Cancer Res Treat. 2013 Aug;141(1):135-44. doi: 10.1007/s10549-013-2669-9. Epub 2013 Aug 24.

PMID:
23974829
11.

UMD-MLH1/MSH2/MSH6 databases: description and analysis of genetic variations in French Lynch syndrome families.

Grandval P, Fabre AJ, Gaildrat P, Baert-Desurmont S, Buisine MP, Ferrari A, Wang Q, Béroud C, Olschwang S.

Database (Oxford). 2013 May 31;2013:bat036. doi: 10.1093/database/bat036. Print 2013.

12.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V.

PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

13.

[Desmoid tumors in children: current strategy].

Oudot C, Defachelles AS, Minard-Colin V, Olschwang S, Fourcade L, Helfre S, Orbach D.

Bull Cancer. 2013 May;100(5):518-28. doi: 10.1684/bdc.2013.1747. Review. French.

PMID:
23695183
14.

Gastric adenocarcinoma in familial adenomatous polyposis can occur without previous lesions.

Ravoire A, Faivre L, Degrolard-Courcet E, Bedenne L, Olschwang S, Rat P, Ortega-Deballon P.

J Gastrointest Cancer. 2014 Sep;45(3):377-9. doi: 10.1007/s12029-013-9504-8. No abstract available.

PMID:
23677534
15.

Design of a core classification process for DNA mismatch repair variations of a priori unknown functional significance.

Grandval P, Fabre AJ, Olschwang S.

Hum Mutat. 2013 Jun;34(6):920-2. doi: 10.1002/humu.22312. Epub 2013 Mar 28. No abstract available.

PMID:
23554159
16.

Semiparametric inference on the penetrances of rare genetic mutations based on a case-family design.

Zhang H, Zeng D, Olschwang S, Yu K.

J Stat Plan Inference. 2013 Feb;143(2):368-377.

17.

Towards a "Lyon molecular signature" to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94 rectal cancers T1-2-3 Nx MO to be the basis of a molecular signature.

Gérard JP, Baulieux J, Doyen J, Gal J, Letouze E, Olschwang S, Chapet O, Romestaing P.

Cancer Radiother. 2012 Dec;16(8):688-96. doi: 10.1016/j.canrad.2012.09.003. Epub 2012 Nov 13.

PMID:
23153504
18.

Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard ML, Dunlop M, Ho JW, Hodgson S, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen H, Gerdes AM, Barker G, Crawford G, Elliott F, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Bishop DT, Burn J; CAPP2 Investigators.

Lancet Oncol. 2012 Dec;13(12):1242-9. doi: 10.1016/S1470-2045(12)70475-8. Epub 2012 Nov 7.

19.

A seven-gene signature aggregates a subgroup of stage II colon cancers with stage III.

Laibe S, Lagarde A, Ferrari A, Monges G, Birnbaum D, Olschwang S; COL2 Project.

OMICS. 2012 Oct;16(10):560-5. doi: 10.1089/omi.2012.0039. Epub 2012 Aug 23.

PMID:
22917480
20.

Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012.

Rahner N, Steinke V, Schlegelberger B, Eisinger F, Hutter P, Olschwang S.

Eur J Hum Genet. 2013 Jan;21(1). doi: 10.1038/ejhg.2012.164. Epub 2012 Aug 15. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk